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Transdermal nitroglycerin patches have been available in the 
United States for several years and have been widely ac- 
cepted by patients and practicing physicians. These devices 
deliver nitroglycerin at a steady rate and, on the basis of 
relatively constant plasma nitroglycerin levels over the 24 h 
application period, it was originally considered that the 
nitroglycerin patches would provide 24 h angina1 prophy- 
laxis. It is clear that this therapeutic goal has not been 
achieved! In short-term dosing studies (1,2), increases in 
exercise time have been documented after patch application, 
but these studies have employed doses greater than those 
commonly employed in clinical practice. With sustained 
therapy, some studies (3,4) reported prolonged duration of 
action, but the majority of investigations (l&7) showed 
little or no improvement in exercise tolerance during once 
daily patch application. 
Development of tolerance to organic nitrates. It has be- 
come apparent that many dosing schedules for the organic 
nitrates lead to the development of tolerance. Treatment 
regimens designed to produce therapeutic effects throughout 
the 24 h period are associated with partial or complete loss of 
therapeutic effect. This has been documented with four 
times daily therapy with 30 mg of isosorbide dinitrate (8), 
once daily application of sustained release isosorbide dini- 
trate ointment (9) and studies with nitroglycerin patches 
(1,5-7). It is of importance to note that there have been no 
well controlled studies in patients with angina during sus- 
tained therapy with nitroglycerin ointment. The only study 
reported with nitroglycerin ointment is that of Reichek et al. 
(lo), in which small doses of nitroglycerin were adniinistered 
three times daily fbr a period of 8 to 12 weeks. The study was 
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open in design and involved only six patients. It was 
reported that the beneficial effects seen during acute therapy 
were maintained during prolonged administration. Zimrin et 
al. (11) recently documented the rapid development of 
tolerance during a 24 h infusion of nitroglycerin. Exercise 
time to the development of angina was increased initially but 
there was no effect after 24 h despite constant plasma 
nitroglycerin levels throughout the infusion period. 
Mechanisms of nitrate tolerance. The mechanisms re- 
sponsible for nitrate tolerance are not completely under- 
stood. There is evidence of neurohumoral activation during 
nitrate therapy with increased catecholamine release and 
activation of the renin-angiotensin system. These alterations 
could modify the effect of nitrate-induced vasodilation. The 
most commonly accepted hypothesis is that during nitrate 
exposure there is depletion of reduced sulfhydryl groups in 
vascular smooth muscle (12). This, in turn, leads to de- 
creased S-nitrosothiol production, diminished activation of 
guanylate cyclase and, ultimately, to decreased cyclic gua- 
nosine monophosphate (GMP) production. The latter agent 
is considered to be responsible for the vasodilating action of 
the organic nitrate. 
Prevention of nitrate tolerance. Hemodynamic studies 
(13) have demonstrated that tolerance to the vascular effect 
of the organic nitrates occurs very rapidly and that these 
effects are reversed during short periods of nitrate with- 
drawal. In an attempt to prevent or reverse tolerance, 
intermittent nitrate therapy has been employed. It has been 
shown (14) that, with oral isosorbide dinitrate, omission of 
the bedtime dose will prevent tolerance. Other studies 
(15,16) with intermittent oral administration of isosorbide 
dinitrate have also documented that the provision of a 
nitrate-free or low nitrate period will prevent the develop- 
ment of attenuation of the antianginal effects. 
There have been studies employing nitroglycerin patches 
in which the devices were removed for periods of several 
hours during each 24 h period. These studies have docu- 
mented that the strategy of patch removal is successful in 
preventing tolerance but, unfortunately, the antianginal ef- 
fects were not assessed throughout the patch application 
period. Thus, in the study of Cowan et al. (5), in which the 
patch was left in place for 12 h each day, the antianginal 
effects were assessed 3.5 h after patch application. Schaer et 
al. (17) applied the patch for 14 h and carried out exercise 
testing at 8 h. Luke et al. (18) left the patch in place for 16 h 
each day and carried out exercise testing 2 and 4 h after 
patch application. 
Present study. The Transderm Nitro Trial Study Group 
(19) reported in this issue of the Journal provides important 
new evidence regarding the efficacy of intermittent nitroglyc- 
erin patch therapy. In this study, the patches were applied 
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each morning and removed after 12 h. Two dosing ranges References 
were studied, with the major end point being the effect on 
treadmill exercise time to the development of moderate 
angina. The studies were carried out after the first applica- 
tion and after 2 and 4 weeks of once daily therapy. The study 
shows that with the smaller doses designed to deliver 5 and 
IO mg of nitroglycerin over 24 h, there was little beneficial 
effect compared with that achieved with placebo. With the 
larger doses of 15 to 20 mg nitroglycerin delivered over 24 h, 
improvement in treadmill walking time was seen over the 12 
h period of patch application and the beneficial effect was 
documented during sustained daily therapy. Although the 
actual increases in exercise time were modest, we now have 
confirmatory evidence that intermittent nitroglycerin patch 
therapy is effective during short- and long-term therapy. The 
study also indicates that the doses employed should be 
higher than those commonly prescribed. 
This study and others employing intermittent nitrate 
therapy raise the question of nitrate dependence and the 
development of rebound phenomena. With exposure to high 
nitrate concentrations as seen in the munitions industry, 
sudden withdrawal from the work environment has been 
followed by myocardial infarction and sudden death in the 
absence of obstructive coronary atherosclerosis. These ob- 
servations suggest the presence of unopposed vasoconstric- 
tor influences becoming manifest during periods of nitrate 
withdrawal. The Transderm Nitro Trial Study Group re- 
ported one death and nine patients with increasing angina 
during the patch-free period of active therapy. These mani- 
festations could represent natural progression of coronary 
disease, but nitrate withdrawal is a distinct possibility. With 
the use of larger intermittent doses of transdermal or oral 
nitrates, rebound phenomena may become apparent. This 
question is one that should be addressed to ensure the safety 
of intermittent nitrate therapy. 
Combination therapy. Does the provision of a nitrate-free 
period compromise therapy? It is apparent that it is not 
possible to provide angina prophylaxis throughout the 24 h 
period with the organic nitrates, without attenuation of their 
effects. In the majority of patients, angina pectoris occurs 
during the working day and intermittent therapy seems 
appropriate. When the occurrence of angina is less predict- 
able and occurs at various times, combination therapy may 
be necessary. The recognition that the majority of ischemic 
events. both symptomatic and asymptomatic, occur early in 
the day is of relevance in considering intermittent therapy. 
This may prove to be another reason to provide combination 
therapy for patients with angina. 
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